



Anatara announces Australian patent grant for Detach®

- **Granting of patent number AU2019204496 strengthens Anatara’s intellectual property position (IP) in the treatment and prevention of diarrhea caused by pathogenic microbes**
- **The patent provides the pathway for Anatara to further pursue commercialisation opportunities for Detach®**
- **Patent expires on 24 August 2038**
- **Piglet challenge study commenced**

MELBOURNE, 16th April 2021: Anatara Lifesciences Ltd (“Anatara” or “the Company”; ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled “Anti-diarrhea formulation which avoids antimicrobial resistance”.

Anatara’s animal health product, Detach®, uses the patent as a non-antibiotic approach to aid in the control of diarrheal disease (known as scour), developed using bromelain, an extract from pineapple stems.

The patent claims cover an oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The patent is fully owned by Anatara and will expire on 24 August 2038.

The Company remains encouraged by the progress in animal health areas, particularly the opportunity to extend into feed products targeting the need for products for growth enhancement without antibiotics or zinc oxide¹.

Commenting on the patent grant, Anatara Chief Executive Officer Steven Lydeamore said “The granting of the patent secures our intellectual property position and is a significant milestone towards commercialising our Detach® animal health product. Scour in piglets is an expensive, debilitating and in some cases, life-threatening condition, and having a product that is registered for use in Australia, we are well placed to leverage our patent as we work towards a commercial deal.”

Piglet challenge study commenced

The BONIFF-SMEC piglet challenge study for enterotoxigenic *Escherichia Coli*, anticipated to be completed in June 2021, has commenced.

¹ Farmers Weekly, 24 September 2020: <https://www.fwi.co.uk/livestock/pigs/survey-highlights-pig-health-worry-ahead-of-zinc-oxide-ban>



The BONIFF-SMEC study is being done in partnership with Ridley Corporation, where Anantara's formulated feed additive is combined with Ridley's semi-moist extruded creep feed for piglets. The project seeks to determine the efficacy of this combined formulation on piglet health, welfare, and performance after weaning and is being conducted at Murdoch University.

Pleasingly, as announced on the 1 February 2021, the University of New England's Poultry Hub Australia successfully completed the ANR-pf poultry challenge study for subclinical and necrotic enteritis. The commercial significance is being evaluated by animal feed companies and poultry producers.

"Having focused our efforts on research and development over a number of years, we have developed a strong animal health pipeline and I look forward to providing the market with an update on the commercial significance of both the pig and poultry challenge trials in the coming months", added Mr Lydeamore.

This announcement has been authorised for release by the directors.

For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anantara Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anantara.com	Sue MacLeman Chair, Anantara Lifesciences Ltd +61 (0) 437 211 200 smacleman@anantara.com

About Anantara Lifesciences Ltd

Anantara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anantara is a life sciences company with expertise in developing products for animal and human health. Anantara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anantara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anantara Lifesciences Limited
Registered Office

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anantara.com | Website anataralifesciences.com

